# Phase 1/2 lymphoma trials recruiting: 189 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 189 trials in phase 1/2 for lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 lymphoma trials: 189 rows for $9.45, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 189
- Recruiting or not yet: 189
- Read on: November 19, 2026

## Trials

The 25 newest of 189, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07932730 | Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell... | University of Michigan Rogel Cancer Center | Phase 1/2 | Not yet recruiting | Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932730) |
| October 29, 2026 | NCT07905261 | Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd | Phase 1/2 | Not yet recruiting | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | 384 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905261) |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 22, 2026 | NCT07890025 | CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study | Hospital Universitario Dr. Jose E. Gonzalez | Phase 1/2 | Not yet recruiting | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890025) |
| October 21, 2026 | NCT07887750 | REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887750) |
| October 20, 2026 | NCT07882641 | BEX101 in B-cell Non-Hodgkin's Lymphoma | Chinese PLA General Hospital | Phase 1/2 | Recruiting | Non-Hodgkin's Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882641) |
| October 8, 2026 | NCT07864701 | Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers | Chengdu Anticancer Bioscience, Ltd. | Phase 1/2 | Recruiting | Advance Solid Tumors, Lymphoma, Non-Hodgkin | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864701) |
| September 14, 2026 | NCT07819188 | SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma | Sinocelltech Ltd. | Phase 1/2 | Not yet recruiting | NHL - Non-Hodgkin's Lymphoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819188) |
| September 14, 2026 | NCT07818499 | A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818499) |
| August 26, 2026 | NCT07788118 | A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 1/2 | Recruiting | Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788118) |
| August 18, 2026 | NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | BeOne Medicines | Phase 1/2 | Not yet recruiting | Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770698) |
| August 10, 2026 | NCT07754890 | Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma | Peking Union Medical College Hospital | Phase 1/2 | Recruiting | Cutaneous T-cell Lymphoma (CTCL) | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754890) |
| August 6, 2026 | NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | Vitruviae | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome, Solid Tumor... | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749976) |
| July 30, 2026 | NCT07735533 | A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | Umoja Biopharma | Phase 1/2 | Recruiting | Lymphoma, B Cell, Lymphoma Non-Hodgkin, High Grade B Cell Lymphoma, Richter Transformation Lymphoma, Grade 3b... | 274 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735533) |
| July 28, 2026 | NCT07730515 | Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma | Evopoint Biosciences Inc. | Phase 1/2 | Recruiting | Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730515) |
| July 16, 2026 | NCT07706959 | New Genotype-guided Treatment in Newly Diagnosed PTCL | Ruijin Hospital | Phase 1/2 | Not yet recruiting | Peripheral T-cell Lymphoma (PTCL) | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07706959) |
| June 22, 2026 | NCT07658352 | A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Shanghai Helioson Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | B-Cell Non-Hodgkin Lymphoma | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658352) |
| May 29, 2026 | NCT07615283 | Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma | Sun Yat-sen University | Phase 1/2 | Not yet recruiting | Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCL | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07615283) |
| May 27, 2026 | NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1/2 | Recruiting | Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström... | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609862) |
| May 27, 2026 | NCT07607925 | A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL | GlaxoSmithKline | Phase 1/2 | Recruiting | Lymphoma, Non-Hodgkin | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07607925) |
| May 22, 2026 | NCT07601607 | Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma | Sun Yat-sen University | Phase 1/2 | Not yet recruiting | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601607) |
| May 13, 2026 | NCT07584889 | Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies | Shenzhen University General Hospital | Phase 1/2 | Recruiting | B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584889) |
| May 11, 2026 | NCT07578077 | Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | City of Hope Medical Center | Phase 1/2 | Recruiting | Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07578077) |
| May 8, 2026 | NCT07575971 | Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute... | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575971) |
| May 8, 2026 | NCT07575919 | Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575919) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Chinese PLA General Hospital | 8 |
| Sun Yat-sen University | 7 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 6 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 5 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 4 |
| M.D. Anderson Cancer Center | 4 |
| Essen Biotech | 4 |
| City of Hope Medical Center | 4 |
| National Cancer Institute (NCI) | 3 |
| Ruijin Hospital | 3 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 3 |
| Shenzhen University General Hospital | 3 |
| Peking Union Medical College Hospital | 2 |
| OHSU Knight Cancer Institute | 2 |
| Princess Maxima Center for Pediatric Oncology | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| [Dizal Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/dizal-pharmaceuticals) | 2 |
| [Haihe Biopharma Co., Ltd.](https://specstream.ai/data/clinical-trials/company/haihe-biopharma-co-ltd) | 2 |
| Children's Oncology Group | 2 |
| Beijing GoBroad Hospital | 2 |
| Nanjing IASO Biotechnology Co., Ltd. | 1 |
| Genfleet Therapeutics (Shanghai) Inc. | 1 |
| Indapta Therapeutics, INC. | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Jonsson Comprehensive Cancer Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 88 |
| United States | 73 |
| France | 25 |
| Spain | 23 |
| United Kingdom | 20 |
| Australia | 20 |
| Italy | 19 |
| South Korea | 18 |
| Germany | 13 |
| Canada | 12 |
| Japan | 11 |
| Brazil | 10 |
| Sweden | 7 |
| Taiwan | 7 |
| Denmark | 5 |
| Israel | 5 |
| Netherlands | 5 |
| Poland | 5 |
| Belgium | 4 |
| Czechia | 4 |
| Turkey (Türkiye) | 4 |
| Chile | 3 |
| Switzerland | 3 |
| Greece | 2 |
| Hungary | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Stucco contractors in the United States](https://specstream.ai/data/businesses/stucco-contractors/united-states)
- [Russian restaurants in the United States](https://specstream.ai/data/businesses/russian-restaurants/united-states)
- [Powder coating companies in the United States](https://specstream.ai/data/businesses/powder-coating-companies/united-states)
- [Orthotics providers in the United States](https://specstream.ai/data/businesses/orthotics-providers/united-states)
- [Mediators in the United States](https://specstream.ai/data/businesses/mediators/united-states)
- [Israeli restaurants in the United States](https://specstream.ai/data/businesses/israeli-restaurants/united-states)
